Lucid Group, Inc. (LCID)

Revance Therapeutics Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Aug 1, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Market Capitalization	7,435	9,094	9,638	12,481	62,644	2,590
Market Cap Growth	11.92%	-5.65%	-22.78%	-80.08%	2318.62%	-
Enterprise Value	6,383	9,086	7,622	11,482	58,064	2,238
Last Close Price	2.42	3.02	4.21	6.83	38.05	10.01
PS Ratio	7.31	11.26	16.19	20.52	2310.66	651.43
PB Ratio	2.32	1.76	1.99	2.87	16.02	2.19
P/TBV Ratio	2.34	2.35	1.99	2.87	16.02	-
EV/Sales Ratio	7.34	11.25	12.80	18.88	2141.70	562.85
Debt / Equity Ratio	0.53	0.48	0.50	0.54	0.56	0.00
Asset Turnover	0.10	0.09	0.07	0.08	0.01	0.00
Inventory Turnover	3.45	3.14	2.53	3.42	2.42	3.56
Quick Ratio	2.80	3.57	3.89	4.20	15.82	3.38
Current Ratio	3.32	4.18	4.72	5.24	16.43	3.64
Return on Equity (ROE)	-50.06%	-54.15%	-61.48%	-31.59%	-101.35%	-87.95%
Return on Assets (ROA)	-20.44%	-20.65%	-23.45%	-20.57%	-20.61%	-37.79%
Return on Capital (ROIC)	-25.42%	-25.12%	-27.50%	-25.33%	-26.26%	-45.75%
Earnings Yield	-41.80%	-29.84%	-29.34%	-10.45%	-4.12%	-27.77%
FCF Yield	-37.37%	-31.93%	-35.28%	-26.45%	-2.36%	-39.76%
Buyback Yield / Dilution	-19.53%	-17.46%	-22.95%	-128.70%	-2882.34%	-20.54%

Updated May 6, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q